Screener
Mineralys Therapeutics, Inc. MLYS Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
FAQ
- What is Mineralys Therapeutics, Inc.'s shares (diluted)?
- Mineralys Therapeutics, Inc. (MLYS) reported shares (diluted) of 82.8M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Mineralys Therapeutics, Inc.'s shares (diluted) increased by 55.8% year-over-year, from 53.2M to 82.8M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s shares (diluted)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s shares (diluted) has grown at a 131.8% compound annual growth rate (CAGR), from 20.6M to 256.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Mineralys Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude